# Bicara Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bicara-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.bicara.com
- Total disclosed funding: $273M
- Latest round: Series C (Dec 12, 2023)
- Investors on record: 16

## About

Based in Massachusetts, US, and founded in 2020, Bicara Therapeutics Inc. is a clinical-stage firm that is developing biologics that combine targeted therapy with tumor modulators. As of March 2023, Claire Mazumdar serves as the CEO of the company. In December 2023, Bicara Therapeutics Inc. raised USD 165 million in series C funding co-led by new investors TPG and Braidwell Lp, with participation from other investors Fairmount Partners, Aisling Capital, and Deerfield Management. Investors Acorn Bioventures, Bioqube Ventures, Eight Roads Ventures, and other investors also participated in the round.  

The company provides pipeline programs, including BCA101 and BCA356. BCA101 is a bifunctional antibody that is beneficial against a variety of tumor types, including head and neck tumors. The firm's dual-action antibodies combine tumor-targeting antibodies' precision with tumor-microenvironment (TME) modulators' capability for a significant impact at the tumor's site. Bicara uses its platform to build bifunctional molecules to target the tumor and deliver the tumor-modulating payload while reducing side effects.

## Funding rounds

- Series C, Dec 12, 2023, $165M — TPG, Aisling Capital, Eight Roads Ventures, Invus [DUP], F-Prime Capital, Premji Invest, Omega Funds, Deerfield Management, RA Capital Management, Janus Henderson Investors, Fairmount Funds Management, Acorn Bioventures, Red Tree Venture Capital, Bioqube Ventures, Piper Heartland Healthcare Capital, Braidwell Lp
- Series B, Mar 6, 2023, $108M — Eight Roads Ventures, Invus [DUP], F-Prime Capital, Premji Invest, Omega Funds, RA Capital Management, Janus Henderson Investors, Acorn Bioventures, Red Tree Venture Capital, Bioqube Ventures, Piper Heartland Healthcare Capital

## Investors

- Eight Roads Ventures (https://capitalatlas.ai/funds/eight-roads-ventures) — Series B, Series C
- Invus [DUP] — Series B, Series C
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series B, Series C
- Premji Invest — Series B, Series C
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series B, Series C
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B, Series C
- Janus Henderson Investors — Series B, Series C
- Acorn Bioventures (https://capitalatlas.ai/funds/acorn-bioventures) — Series B, Series C
- Red Tree Venture Capital (https://capitalatlas.ai/funds/red-tree-venture-capital) — Series B, Series C
- Bioqube Ventures (https://capitalatlas.ai/funds/bioqube-ventures) — Series B, Series C
- Piper Heartland Healthcare Capital — Series B, Series C
- TPG (https://capitalatlas.ai/funds/tpg) — Series C
- Aisling Capital (https://capitalatlas.ai/funds/aisling-capital) — Series C
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series C
- Fairmount Funds Management — Series C
- Braidwell Lp — Series C